"The First AI Drug Delivery Stock" METiS Pharmaceuticals has officially passed the HKEX hearing. According to the prospectus, the funds raised will be used for the technological R&D of AI infrastructure and nanomaterial platforms, advancing clinical trials of pipelines under development, and expanding applications in animal health and anti-aging fields. Founded in 2020 by Dr. Hongmin Chen, a member of both the U.S. National Academy of Sciences and National Academy of Engineering, and Dr. Caida Lai from MIT, METiS Pharmaceuticals focuses on leveraging targeted drug delivery and drug discovery technologies to accelerate the development of innovative therapies for major diseases. Its self-developed NanoForge platform integrates a library of over ten million lipids and multiple AI technologies, enabling precise targeted delivery to eight key organs and tissues. Currently, METiS Pharmaceuticals boasts over 10 pipeline products covering multiple fields such as oncology and the immune system. In 2025, the company achieved revenue of RMB 105 million, a nearly 70-fold increase year-on-year, with a gross profit margin rising to 98.2%.